Key result
A custom DNA resequencing array identified known or novel potentially pathogenic heterozygous single-nucleotide variants in 31% of unrelated patients with hypertrophic cardiomyopathy.
Why the study?
Does a custom DNA resequencing array effectively detect pathogenic genetic variants in patients with hypertrophic cardiomyopathy?
Observational (n=122)
Does a custom DNA resequencing array effectively detect pathogenic genetic variants in patients with hypertrophic cardiomyopathy?
A custom DNA resequencing array provides a rapid and efficient method for first-tier mutation screening in hypertrophic cardiomyopathy, detecting potentially pathogenic variants in 31% of patients.
Answers are grounded in this paper and cite their sources.
Should not yet change HCM genetic testing practice; leaves open array utility pending prospective validation.
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease (1/500) and the most common cause of sudden cardiac death in young people. Pathogenic mutation detection of HCM is having a growing impact on the medical management of patients and their families. However, the remarkable genetic and allelic heterogeneity makes molecular analysis by conventional methods very time-consuming, expensive and difficult to realise in a routine diagnostic molecular laboratory. METHOD AND RESULTS: The authors used their custom DNA resequencing array which interrogates all possible single-nucleotide variants on both strands of all exons (n=160), splice sites and 5'-untranslated region of 12 HCM genes (27 000 nucleotides). The results for 122 unrelated patients with HCM are presented. Thirty-three known or novel potentially pathogenic heterozygous single-nucleotide variants were identified in 38 patients (31%) in genes MYH7, MYBPC3, TNNT2, TNNI3, TPM1, MYL3 and ACTC1. CONCLUSIONS: Although next-generation sequencing will replace all large-scale sequencing platforms for inherited cardiac disorders in the near future, this HCM resequencing array is currently the most rapid, cost-effective and reasonably efficient technology for first-tier mutation screening of HCM in clinical practice. Because of its design, the array is also an appropriate tool for initial screening of other inherited forms of cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Fokstuen et al. (2011) conducted an observational in Hypertrophic cardiomyopathy (n=122). Custom DNA resequencing array was evaluated on Identification of known or novel potentially pathogenic heterozygous single-nucleotide variants. A custom DNA resequencing array identified known or novel potentially pathogenic heterozygous single-nucleotide variants in 31% of unrelated patients with hypertrophic cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: